hemostemix-logo-small.jpg
Hemostemix Announces Director Resignation
22 nov. 2019 16h30 HE | Hemostemix Inc.
CALGARY, Alberta, Nov. 22, 2019 (GLOBE NEWSWIRE) -- Hemostemix Inc. (“Hemostemix” or the “Company”) (TSX VENTURE: HEM; OTCQB: HMTXF), a biotechnology company focused on developing and...
hemostemix-logo-small.jpg
Hemostemix Provides Corporate Update
19 nov. 2019 08h30 HE | Hemostemix Inc.
CALGARY, Alberta, Nov. 19, 2019 (GLOBE NEWSWIRE) -- Hemostemix Inc. (“Hemostemix” or the “Company”) (TSX VENTURE: HEM; OTCQB: HMTXF), a biotechnology company developing and commercializing...
hemostemix-logo-small.jpg
Hemostemix Provides Corporate Update
31 oct. 2019 08h30 HE | Hemostemix Inc.
CALGARY, Alberta, Oct. 31, 2019 (GLOBE NEWSWIRE) -- Hemostemix Inc. (“Hemostemix” or the “Company”) (TSX VENTURE: HEM; OTCQB: HMTXF), is a biotechnology company developing and commercializing...
hemostemix-logo-small.jpg
Hemostemix Announces Positive Results and Conclusions Reported in Phase II CLI Trial Abstract
21 oct. 2019 08h30 HE | Hemostemix Inc.
CALGARY, Alberta, Oct. 21, 2019 (GLOBE NEWSWIRE) -- Hemostemix Inc. (“Hemostemix” or the “Company”) (TSX VENTURE: HEM; OTCQB: HMTXF), a biotechnology company developing and commercializing...
hemostemix-logo-small.jpg
Hemostemix Announces Commencement of Arbitration
17 oct. 2019 07h30 HE | Hemostemix Inc.
CALGARY, Alberta, Oct. 17, 2019 (GLOBE NEWSWIRE) -- Hemostemix Inc. (“Hemostemix” or the “Company”) (TSX VENTURE: HEM; OTCQB: HMTXF), a biotechnology company focused on developing and...
hemostemix-logo-small.jpg
Hemostemix Announces $2 Million Loan Facility
01 août 2019 08h30 HE | Hemostemix Inc.
NOT FOR DISTRIBUTION TO U.S. NEWS WIRE SERVICES OR DISSEMINATION IN THE UNITED STATES CALGARY, Alberta, Aug. 01, 2019 (GLOBE NEWSWIRE) -- Hemostemix Inc. (“Hemostemix” or the “Company”) (TSX...
hemostemix-logo-small.jpg
Hemostemix Announces Financing Update and Interim CFO Appointment
11 juil. 2019 08h30 HE | Hemostemix Inc.
CALGARY, Alberta, July 11, 2019 (GLOBE NEWSWIRE) -- Hemostemix Inc. (“Hemostemix” or the “Company”) (TSX VENTURE: HEM; OTCQB: HMTXF), a biotechnology company focused on developing and...
hemostemix-logo-small.jpg
Hemostemix Announces Ongoing Phase II CLI Trial Abstract Accepted for Presentation by Canadian Society for Vascular Surgery
02 juil. 2019 08h30 HE | Hemostemix Inc.
CALGARY, Alberta, July 02, 2019 (GLOBE NEWSWIRE) -- Hemostemix Inc. (“Hemostemix” or the “Company”) (TSX VENTURE: HEM; OTCQB: HMTXF), a biotechnology company developing and commercializing...
hemostemix-logo-small.jpg
Hemostemix Announces Enrollment Update for the ACP-01 Phase II Critical Limb Ischemia Clinical Trial
27 juin 2019 08h30 HE | Hemostemix Inc.
CALGARY, Alberta, June 27, 2019 (GLOBE NEWSWIRE) -- Hemostemix Inc. (“Hemostemix” or the “Company”) (TSX VENTURE: HEM; OTCQB: HMTXF) is pleased to announce that it has enrolled a total of forty (40)...
hemostemix-logo-small.jpg
Hemostemix Announces Resignation of CFO
25 juin 2019 08h30 HE | Hemostemix Inc.
CALGARY, Alberta, June 25, 2019 (GLOBE NEWSWIRE) -- Hemostemix Inc. (“Hemostemix” or the “Company”) (TSX VENTURE: HEM; OTCQB: HMTXF), a biotechnology company focused on developing and...